is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs, particularly in the fields of oncology and autoimmune diseases. The company leverages its expertise in drug formulation and delivery to create targeted treatment options that aim to improve patient outcomes and quality of life. By emphasizing research and development, Conduit seeks to advance its pipeline of product candidates through various stages of clinical trials, with the ultimate goal of bringing new therapies to market that address critical health challenges faced by patients.
Conduit Pharmaceuticals Inc. (NASDAQCDT) shares are trading higher Thursday after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset, AZD1656. Here's what you need to know.
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit plans Phase 2 trials for AZD1656 and AZD5658 in 2024.
